20/20 Biolabs Inc

This proposal asks shareholders to approve an amendment and restatement of the Company’s certificate of incorporation to increase the authorized common stock from 50 million to 500 million shares and to remove provisions relating to several series of preferred stock that have been converted. Management and the board argue the increase is primarily to replenish the pool of authorized shares to accommodate potential future issuances — including potential conversions of Series E convertible preferred stock issued under a November 17, 2025 Purchase Agreement — and to increase flexibility for grants under equity plans and other corporate actions without the delay and expense of special meetings. The filing discloses that Series E preferred shares convert at a variable price (subject to a floor tied to Nasdaq rules), making conversion outcomes uncertain and potentially requiring a materially greater number of authorized shares than currently available. The company acknowledges the potential anti-takeover implications of an increase in authorized shares, noting additional shares could be issued in ways that dilute challengers or otherwise affect control, but states there are no present plans to use the amendment as an anti-takeover device. Approval requires a vote of a majority of outstanding shares, and the board recommends a “FOR” vote. For an analyst evaluating corporate governance and financing flexibility, the size of the requested increase (10x) and the explicit linkage to convertible preferred instruments and a proposed equity plan (Proposal 4) suggest management is planning to materially enlarge the available capitalization headroom; this enhances flexibility for fundraising, equity compensation and conversion mechanics while also increasing dilution risk for existing holders. The board’s recommendation emphasizes operational and administrative efficiency (avoiding special meetings) and accommodation of known contractual conversion exposures, but the proposal should be evaluated against potential dilution outcomes, timing of subsequent issuances, and whether governance safeguards (e.g., pre-emptive rights or limits on insider issuances) are adequate. Overall, the proposal transfers substantial issuance power to the board, which benefits corporate agility but raises shareholder concerns about future dilution unless accompanied by clear issuance policies and disclosure commitments.

This management-sponsored proposal requests shareholder approval of a new long-term incentive plan— the 2026 Equity Incentive Plan—authorizing an initial reserve of 5,000,000 shares and an annual automatic increase equal to 7% of outstanding shares each January 1. Management frames the plan as necessary to attract, retain, and motivate employees, consultants, and directors by aligning their interests with stockholders through options, restricted stock, SARs, performance awards, and other equity instruments. The plan grants broad discretion to the compensation committee (or board) over award types, terms, recipients, exercise prices, vesting schedules, performance criteria, and other features, and allows for cash or share settlement; these flexibilities are typical but transfer substantial grant and pricing authority to the administrator. Key governance considerations include (a) the sizable initial reserve and the recurring formulaic share increases which, combined with the charter amendment in Proposal 3, could produce meaningful dilution over time; (b) the plan’s allowance for repricing only with committee approval but subject to potential stockholder approval requirements for certain repricings; and (c) change-in-control and acceleration provisions that permit discretionary or formulaic vesting triggers. The plan contains customary tax and Section 409A provisions but also permits selective, non-uniform awards across participants, which could concentrate benefits among insiders unless robust disclosure and clawback/forfeiture safeguards are enforced. For an institutional evaluator, critical follow-ups should include modeling dilution under various annual increases and grant rates, assessing historical grant practices and insider benefit concentration, and confirming whether the board will adopt clear issuance limits, minimum vesting/holding periods, and strong clawback or anti-dilution protections. The board’s recommendation emphasizes competitive compensation needs and alignment with stockholder interests, but shareholders should weigh those benefits against potential dilution and governance controls over future grants.

This proposal asks shareholders to grant the proxies authority to adjourn the Annual Meeting, potentially repeatedly, to a later date to solicit additional proxies if there are insufficient votes to approve one or more proposals at the time of the meeting. Management seeks this authority to provide flexibility to continue solicitation efforts without having to reconvene a new meeting and to permit additional time to obtain requisite majorities. The proposal is procedural and is commonly included to avoid having to reschedule or convene a second meeting; it requires a majority vote of shares present or represented by proxy. The proxy statement emphasizes that stockholders who have already submitted proxies retain the right to revoke them prior to their use if the meeting is adjourned. For governance-minded investors, the primary consideration is that adjournment authority can be used to continue solicitations, which may be routine, but could also be used in contested or contentious circumstances to seek additional vote counts; however, because this company’s other proposals are management-sponsored and the board recommends a “FOR” vote, the risk of extended adjournments for tactical reasons appears limited. The board’s recommendation cites efficiency and the practical necessity of securing approval thresholds, and this proposal does not on its face change corporate rights or capital structure.